![Jay Cross](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jay Cross
Direttore Finanziario/CFO presso
Senti Biosciences, Inc.
Patrimonio netto: - $ in data 30/06/2026
Profilo
John Harry Cross is currently Chief Financial Officer at Senti Biosciences Holdings, Inc. since 2026 and Chief Financial Officer at Senti Biosciences, Inc. since 2025.
Formerly, Mr. Cross was Chief Financial Officer, Treasurer & Secretary at Sonnet BioTherapeutics Holdings, Inc. from 2019 to 2025, Managing Director-Healthcare Investment Banking at Chardan Capital Markets LLC from 2015 to 2019, Director at Alere Financial Partners from 2014 to 2015, and Chief Financial & Business Officer at Sonnet BioTherapeutics, Inc. Education includes undergraduate studies at Washington & Lee University and graduate studies at Yale School of Medicine.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
-.--% | 27/03/2026 | 0 ( -.--% ) | - $ | 30/06/2026 |
Posizioni attive di Jay Cross
| Società | Posizione | Inizio |
|---|---|---|
Senti Biosciences, Inc.
 Senti Biosciences, Inc. BiotechnologyHealth Technology Develops a synthetic biology platform that enables to program next-generation cell and gene therapies | Direttore Finanziario/CFO | 03/03/2025 |
Precedenti posizioni note di Jay Cross
| Società | Posizione | Fine |
|---|---|---|
| SONNET BIOTHERAPEUTICS | Direttore Finanziario/CFO | 21/02/2025 |
Chardan Capital Markets LLC
 Chardan Capital Markets LLC Investment Banks/BrokersFinance Provides brokerage services | Corporate Officer/Principal | 01/03/2019 |
Alere Financial Partners
 Alere Financial Partners Investment ManagersFinance Provides investment research | Direttore/Membro del Consiglio | 01/06/2015 |
Sonnet BioTherapeutics, Inc.
 Sonnet BioTherapeutics, Inc. BiotechnologyHealth Technology Develops immuno-oncology therapeutics | Direttore Finanziario/CFO | - |
Formazione di Jay Cross
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
35
Relazioni di 1° grado
7
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 7 |
|---|---|
Washington & Lee University
 Washington & Lee University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Chardan Capital Markets LLC
Chardan Capital Markets LLC Investment Banks/BrokersFinance Provides brokerage services | Finance |
Alere Financial Partners
Alere Financial Partners Investment ManagersFinance Provides investment research | Finance |
Yale School of Medicine
 Yale School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sonnet BioTherapeutics, Inc.
Sonnet BioTherapeutics, Inc. BiotechnologyHealth Technology Develops immuno-oncology therapeutics | Health Technology |
Sonnet BioTherapeutics Holdings, Inc.
 Sonnet BioTherapeutics Holdings, Inc. BiotechnologyHealth Technology Develops immuno-oncology therapeutics | Health Technology |
Senti Biosciences, Inc.
Senti Biosciences, Inc. BiotechnologyHealth Technology Develops a synthetic biology platform that enables to program next-generation cell and gene therapies | Health Technology |
